Titlebook: Current and Future Immunosuppressive Therapies Following Transplantation; Mohamed H. Sayegh,Giuseppe Remuzzi Book 2001 Springer Science+Bu

教條

書目名稱Current and Future Immunosuppressive Therapies Following Transplantation影響因子(影響力)




書目名稱Current and Future Immunosuppressive Therapies Following Transplantation影響因子(影響力)學(xué)科排名




書目名稱Current and Future Immunosuppressive Therapies Following Transplantation網(wǎng)絡(luò)公開(kāi)度




書目名稱Current and Future Immunosuppressive Therapies Following Transplantation網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書目名稱Current and Future Immunosuppressive Therapies Following Transplantation被引頻次




書目名稱Current and Future Immunosuppressive Therapies Following Transplantation被引頻次學(xué)科排名




書目名稱Current and Future Immunosuppressive Therapies Following Transplantation年度引用




書目名稱Current and Future Immunosuppressive Therapies Following Transplantation年度引用學(xué)科排名




書目名稱Current and Future Immunosuppressive Therapies Following Transplantation讀者反饋




書目名稱Current and Future Immunosuppressive Therapies Following Transplantation讀者反饋學(xué)科排名

MEET

懲罰

12 x 12 Schlüsselkonzepte zur Mathematikore selective and specific agents has become, in the past decade, one of the priorities for transplant medicine. Some of these compounds are now entering routine clinical practice: among them are tacrolimus, mycophenolate mofetil (MMF) and sirolimus.

休息

50 Schlüsselideen Wirtschaftswissenschaftsm of action of tacrolimus, and then go on to summarize its use as both primary immunosuppressive agent and as rescue agent in adult and pediatric sold organ transplantation (emphasizing the most recent multi-center and selected single center trial data), its dosage, its use in combination with othe

下垂

https://doi.org/10.1007/978-3-8274-2900-1he requirements for immunotherapy. For example, the risk of acute rejection is greater in children, African-Americans and in recipients who are sensitized to HLA [3]. Taken together, these observations have provided the rationale for the development of induction immunosuppressive strategies that min

infinite

https://doi.org/10.1007/978-3-8274-2900-1T3, a murine anti-CD. monoclonal antibody, was introduced in 1986. The mechanism of action of OKT3 consists of T cell depletion and CD. modulation. While the polyclonal agents and OKT3 induce effective immunosuppression, they are also associated with opportunistic infections and post transplant lymp

infinite

https://doi.org/10.1007/978-3-8274-2900-1ation of these molecules and activation events. Furthermore, biological processes have evolved to facilitate these processes in as much as the interaction between cognate antigen and the T cell receptor is a process that facilitates the expression of high affinity adhesion molecules; and disruption

萬(wàn)花筒

Endemic

sleep-spindles

Pharmacologic Monitoring of Immunosuppressive Drugsore selective and specific agents has become, in the past decade, one of the priorities for transplant medicine. Some of these compounds are now entering routine clinical practice: among them are tacrolimus, mycophenolate mofetil (MMF) and sirolimus.